- Home
- RDCM vs CTNM Comparison
RDCM vs CTNM Comparison
Compare RDCM & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDCM
- CTNM
- Stock Information
- Founded
- RDCM 1985
- CTNM 2009
- Country
- RDCM Israel
- CTNM United States
- Employees
- RDCM N/A
- CTNM N/A
- Industry
- RDCM Computer peripheral equipment
- CTNM
- Sector
- RDCM Technology
- CTNM
- Exchange
- RDCM Nasdaq
- CTNM Nasdaq
- Market Cap
- RDCM 179.7M
- CTNM 114.1M
- IPO Year
- RDCM 1997
- CTNM 2024
- Fundamental
- Price
- RDCM $12.72
- CTNM $3.95
- Analyst Decision
- RDCM Strong Buy
- CTNM Strong Buy
- Analyst Count
- RDCM 2
- CTNM 4
- Target Price
- RDCM $15.00
- CTNM $23.75
- AVG Volume (30 Days)
- RDCM 30.7K
- CTNM 88.4K
- Earning Date
- RDCM 05-14-2025
- CTNM 05-16-2025
- Dividend Yield
- RDCM N/A
- CTNM N/A
- EPS Growth
- RDCM 79.17
- CTNM N/A
- EPS
- RDCM 0.43
- CTNM N/A
- Revenue
- RDCM $61,009,000.00
- CTNM N/A
- Revenue This Year
- RDCM $14.93
- CTNM N/A
- Revenue Next Year
- RDCM $10.74
- CTNM N/A
- P/E Ratio
- RDCM $28.02
- CTNM N/A
- Revenue Growth
- RDCM 18.23
- CTNM N/A
- 52 Week Low
- RDCM $8.85
- CTNM $3.69
- 52 Week High
- RDCM $15.98
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- RDCM 65.35
- CTNM N/A
- Support Level
- RDCM $11.67
- CTNM N/A
- Resistance Level
- RDCM $12.15
- CTNM N/A
- Average True Range (ATR)
- RDCM 0.56
- CTNM 0.00
- MACD
- RDCM 0.20
- CTNM 0.00
- Stochastic Oscillator
- RDCM 96.92
- CTNM 0.00
About RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.